NHTSA opened recall query RQ26006 on November 6, 2026, to assess whether the remedy for Waymo’s school-bus software recall addressed reports of vehicles passing stopped buses. The inquiry covers 2,895 vehicles equipped with Waymo’s fifth-generation automated driving system (ADS), according to the NHTSA investigation resume.

What NHTSA is investigating

The Office of Defects Investigation (ODI), part of NHTSA, is assessing the remedy for Recall 25E084 and seeking the causes of reports that followed it. The recall concerns software that may cause a vehicle to pass a stopped school bus when its red lights are flashing and/or its stop arm is extended. The intended behavior is for the vehicle to remain stopped.

NHTSA says a majority of the incidents reported during its earlier preliminary evaluation, PE25013, occurred after the remedy date. That makes the performance of the remedy central to RQ26006: the agency is examining whether it addressed the reported behavior. The query is an open review, not a final determination about the remedy.

Completing a software update is one milestone; whether it addresses the reported behavior is the question this query is designed to answer.

How the recall and query fit together

NHTSA’s resume says the software update had been completed for affected vehicles on November 17, 2025. Waymo filed Recall 25E084 on December 10, 2025. The agency’s resume lists RQ26006 as opened on November 6, 2026.

The dates mark separate steps: completion of the update, filing of the recall, and the opening of the later query. NHTSA’s stated task is to assess the remedy and investigate reports that came after its completion.

What the citation entries count

The NHTSA resume lists eight entries in the “Other” category and describes them as traffic citations provided by Austin Independent School District. The agency does not identify those entries as the total number of incidents.

The query’s scope is specific: 2,895 vehicles with Waymo’s fifth-generation ADS, and a review of the remedy for Recall 25E084 in light of post-remedy reports.